Latest news with #Predictive
Time of India
23-05-2025
- Science
- Time of India
CSIR-SERC to come up with safeguards for railway bridges
Chennai: City researchers are working to frame guidelines for the railways to monitor and evaluate the structural health of its bridges. Experts from CSIR-Structural Engineering Research Centre (SERC) in Taramani are drafting guidelines after conducting studies on 10 railway bridges across the country. They also installed devices in two bridges to absorb high-impact forces caused by increased speed and axle load, thereby reducing structural stress. The guidelines aim to help railway engineers assess and strengthen both new and existing bridges to handle longitudinal forces generated when high-speed trains with heavier axle loads pass over them. "Our guidelines will help evaluate the longitudinal force on the substructure of railway bridges, both steel and prestressed concrete, and suggest techniques to mitigate them. This can be adopted for new constructions as well as upgrades," said N Anandavalli, director, CSIR-SERC, on the sidelines of a conference on Wednesday. Following the studies, SERC installed shock transmission units (STUs) in a concrete bridge near Chidambaram and a steel bridge near Puttur, Andhra Pradesh. STUs are hydraulic devices that remain flexible under normal conditions but become rigid during sudden forces like braking or seismic activity, absorbing energy and protecting the structure. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trade Bitcoin & Ethereum – No Wallet Needed! IC Markets Start Now Undo Earlier, Ravindra Kumar Goel, principal executive director (bridges), ministry of railways, noted that of the 1.6 lakh railway bridges in the country, 34,000 are more than 100 years old. Both the speed of trains and their axle load increased over the years. Since 1903, the axle load alone increased by 33%. He was speaking at CSIR-SERC's Diamond Jubilee conference on Monitoring, Assessment and Predictive Maintenance of Critical Infrastructures (i-MAP 2025). T Archunan, Director (Projects), Chennai Metro Rail Limited, pointed to the disconnect between India's research institutions and field implementation. He stressed the need for institutes such as SERC and Indian Institutes of Technology (IITs) to align theoretical work with practical needs to improve execution and reduce reliance on foreign technology.
Yahoo
20-05-2025
- Business
- Yahoo
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"
Latest developments expand Predictive's AI-driven drug discovery platform to include biomarker discovery and drug repurposing With the global biomarker discovery market valued at $14.5 billion in 2024 and projected to grow at a 19.4% CAGR through 2030, Predictive Oncology is poised to lead in precision oncology innovation PITTSBURGH, May 20, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following shareholder update recapping recent progress: To Our Shareholders,Thank you for the opportunity to share an update on the progress we're making at Predictive Oncology as we work to position ourselves as a leader—and partner of choice—in the critical and fast-evolving field of AI-driven biomarker and drug I am more confident than ever that our unique combination of assets and capabilities—most notably our vast biobank of diverse live-cell tumor specimens—sets us apart in the industry. These advantages provide us with a strong foundation to drive long-term value and play a significant role in shaping the future of cancer treatment, drug development, and clinical decision-making Survival Prediction Models in Ovarian CancerOne of our most important achievements this past year was our collaboration with UPMC Magee-Womens Hospital, where we successfully developed AI-powered multi-omic machine learning models that predict short- and long-term survival outcomes in ovarian cancer patients—outperforming models based solely on clinical breakthrough results were presented at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting in June implications are far-reaching. Beyond improving early drug discovery, these models may also enhance clinical decision-making by helping providers tailor treatments to individual patients more effectively—potentially improving patient monitoring, management, and is particularly important for high-grade serous ovarian cancer, a difficult cancer to treat, where relapse rates after frontline treatment remain high. We are actively refining these models with the goal of integrating them into clinical practice at leading cancer centers Biomarker DiscoveryBuilding on the success of the Magee study, we identified novel ovarian cancer biomarkers linked to patient survival and drug response using advanced deep learning methods. These insights were achieved using our existing datasets and believe biomarker discovery represents a transformative opportunity for our AI platform—not only in ovarian cancer, but across a wide range of tumor types. According to Grand View Research, the biomarker discovery market reached $14.5 billion in 2024, with expected growth of 19.4% CAGR through 2030. We are actively exploring strategic partnerships with biopharmaceutical companies and healthcare networks to further capitalize on this Drug Discovery SuccessOur efforts in early-stage drug discovery remain core to our mission. With clinical trial failure rates in oncology remaining high, particularly in Phases II and III, we address a critical industry challenge: the late introduction of patient integrating real-world diversity from our biobank of 150,000 tumor samples across 137 cancer types, we validate AI drug response predictions with wet-lab testing in the earliest stages—boosting the Probability of Technical Success (PTS) and improving decision-making for target selection, clinical trial design, and pipeline capability allows our partners to accelerate timelines, reduce risk, and optimize R&D investments—making it a central component of ongoing business development Value in Drug RepurposingA unique and often overlooked advantage of our platform is its ability to repurpose previously abandoned oncology drugs. Recently, we screened a curated set of such compounds using active machine learning and identified three candidates worth re-evaluating in ovarian and colon capability provides enormous value to drug developers by unlocking the potential of shelved assets and efficiently transitioning them back into clinical readiness. We are now applying this approach to a broader range of publicly available compounds. Expanding ChemoFx® and Personalized Treatment SelectionIn January, we announced plans to expand the reach of our flagship assay, ChemoFx®, into Europe and to broaden its availability in the United States. ChemoFx is a live-cell tumor profiling assay that uses a patient's own cells to measure chemotherapy responses in vitro, providing personalized guidance for treatment alongside our BioSpeciFx® molecular biomarker portfolio, ChemoFx allows oncologists to determine which chemotherapies are most likely to benefit a specific patient—initially focusing on gynecologic cancers with plans to expand to additional tumor platform directly supports our AI-driven drug discovery initiatives by generating high-quality data that feeds into predictive models and supports biomarker discovery, companion diagnostics, and clinical trial AheadThe progress we've made in 2024 lays a strong foundation for future growth. With a powerful combination of AI innovation, proprietary data, and deep scientific expertise, Predictive Oncology is uniquely positioned to lead the next wave of advancement in precision are grateful to our team—past and present—for their tireless commitment to our mission, and to you, our shareholders, for your continued support. I remain optimistic about the road ahead and look forward to updating you on the exciting opportunities we are actively pursuing. Sincerely, Raymond Raymond VennareChief Executive Officer and Chairman of the Board, Predictive Oncology About Predictive Oncology Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company's scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company's vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry's broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA laboratory facility. Predictive Oncology is headquartered in Pittsburgh, PA. Investor Relations Contact: Mike MoyerLifeSci Advisors, LLC mmoyer@ Forward-Looking Statements Certain statements made in this press release are 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These forward- looking statements reflect Predictive Oncology's current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about Predictive Oncology's operations and the investments Predictive Oncology makes. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'would,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Predictive Oncology's actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading 'Risk Factors' in Predictive Oncology's filings with the SEC. Except as expressly required by law, Predictive Oncology disclaims any intent or obligation to update these forward-looking statements. Predictive Oncology does not give any assurance that Predictive Oncology will achieve its expectations described in this press in to access your portfolio
Yahoo
03-03-2025
- Business
- Yahoo
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States Renovaro's recent strategic acquisition of BioSymetrics vastly expands Predictive Oncology's biomarker and drug discovery opportunities and the development of diagnostic applications in oncology Merger expected to enhance shareholder value, accelerate business development efforts and solidify positioning in the capital markets PITTSBURGH, March 03, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced that it has received the first tranche of financing from Renovaro Biosciences, Inc. (NASDAQ: RENB) to initiate the integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Predictive and Renovaro reiterate their unwavering commitment to improving the outcomes of cancer patients through earlier diagnosis, biomarker discovery and targeted therapies by integrating and leveraging Predictive's AI-driven drug discovery platform, vast biobank of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data with Renovaro's multi-disciplinary artificial intelligence, multi-omic and multi-modal data expertise. 'Since we first announced our intentions to merge with Renovaro Biosciences in January, Predictive and Renovaro have worked diligently to thoroughly evaluate the expanded market opportunities created by this merger. Renovaro's recent acquisition of BioSymetrics, together with our ability to launch ChemoFx in Europe, represent significant steps forward in these efforts,' said Raymond Vennare, Chairman and Chief Executive Officer of Predictive Oncology. Messrs. Vennare and David Weinstein, CEO of Renovaro added, 'Although we have been working very hard over the past two months to anticipate all contingencies, the complicated logistics of combining our core platform technologies and international team of experts still requires a bit more effort. Nevertheless, we fully expect to sign a definitive merger agreement within the next few weeks.' Predictive Oncology does not intend to discuss or disclose further developments regarding these discussions unless and until its Board of Directors has approved a transaction or otherwise determined that further disclosure is appropriate or required by law. About Renovaro Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio, an advanced cell-gene immunotherapy company, and Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support. About Predictive Oncology Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early biomarker and drug discovery and enable drug development for the benefit of cancer patients worldwide. The company's proprietary AI/ML platform has been scientifically validated to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company's vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry's broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA. Contact:Tim McCarthyLifeSci Advisors, LLCtim@ Forward-Looking Statements:Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'would,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading 'Risk Factors' in our filings with the SEC. Except as expressly required by law, the company disclaims any intent or obligation to update these forward-looking in to access your portfolio
